This job is closed
We regret to inform you that the job you were interested in has been closed. Although this specific position is no longer available, we encourage you to continue exploring other opportunities on our job board.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a 'Global Pharma Innovator with Competitive Advantage in Oncology,' Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. This position will lead the valuation processes for in-licensing, out-licensing, co-development and/or acquiring opportunities. Accountable to own the financial evaluation model developed in close collaboration with Global Business Development (US, Japan, EU teams), Finance (Corporate FP&A & R&D), Global Commercial & Strategy, Global Forecasting & Insights and Global Project Management. Successful execution will involve working cross-functionally to gather relevant information, synthesize the materials, and develop comprehensive opportunity assessments consistent with our corporate business development strategy. This position may lead a small team and will report to the Head of Forecasting/Business Analytics and Deal Valuations.
A Smarter and Faster Way to Build Your Resume